REGENXBIO Sets Stage for Crucial 2025 Earnings Call as Gene Therapy Pipeline Nears Finish Line

ROCKVILLE, Md. – February 25, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) has scheduled a conference call for March 5, where it will unveil its fourth-quarter and full-year 2025 financial results. For investors, analysts, and patients, this call is more than a standard financial update; it represents a critical checkpoint for a company at the precipice of transforming from a clinical-stage pioneer into a commercial-stage gene therapy powerhouse. With multiple late-stage treatments approaching key milestones, the upcoming discussion will provide a vital look into the company's financial health, operational readiness, and strategic path forward in the high-stakes biotechnology sector.

A Financial Report Card Under Scrutiny

The financial narrative for REGENXBIO in 2025 has been complex. While the company is projected to report a substantial year-over-year revenue increase for 2025, estimated around 128% to approximately $189.9 million, this figure is largely powered by a significant one-time payment. In March 2025, a partnership with Nippon Shinyaku for its MPS I and MPS II therapies, RGX-111 and RGX-121, brought in a $110 million upfront payment, dramatically boosting Q1 revenue.

However, subsequent quarters saw the company miss analyst expectations in Q2 before rebounding with a beat on both earnings per share (EPS) and revenue in Q3. This volatility underscores the reliance on partnership milestones and the underlying costs of advancing a sophisticated gene therapy pipeline. Analysts anticipate a full-year 2025 EPS of around -$3.18, reflecting continued heavy investment in research and development. R&D expenses in Q3 alone stood at $56.1 million.

A key metric for investors on March 5 will be the company’s cash runway. As of September 30, 2025, REGENXBIO reported having $302 million in cash and equivalents, projecting this would fund operations into early 2027. This guidance, however, excludes potentially lucrative milestone payments and the value of a possible Priority Review Voucher (PRV), making the updated financial outlook and cash burn rate a focal point of the call.

Pipeline Nears Commercial Finish Line

Beyond the balance sheet, the true excitement surrounds REGENXBIO's operational progress. The company's late-stage pipeline is poised to deliver transformative, one-time treatments for devastating rare and retinal diseases, with several programs nearing pivotal moments.

The most immediate catalyst is clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. REGENXBIO submitted its Biologics License Application (BLA) to the FDA in March 2025, and with a PDUFA date having passed on February 8, 2026, news on a potential approval is imminent. The company has already targeted a commercial launch for early 2026, positioning RGX-121 to become the first-ever gene therapy for the condition. Successful approval could also grant REGENXBIO a valuable PRV, which can be used to expedite the review of another drug or sold for a significant sum.

Equally significant is the progress of RGX-202 for Duchenne muscular dystrophy, a severe muscle-wasting disorder. The company completed enrollment for its pivotal trial in October 2025, ahead of schedule, with topline results anticipated in the second quarter of 2026. Based on promising early data, REGENXBIO plans to file for accelerated approval in mid-2026, aiming for a 2027 commercial launch. The company has highlighted RGX-202’s differentiated design, which it believes could make it a best-in-class therapy in a competitive field.

Furthermore, the collaboration with pharmaceutical giant AbbVie on surabgene lomparvovec (ABBV-RGX-314) for chronic retinal diseases continues to advance. Enrollment is complete in pivotal trials for wet age-related macular degeneration (wet AMD), with crucial data expected in the fourth quarter of 2026. A separate program for diabetic retinopathy is also moving toward a global pivotal study, holding the potential to become the first gene therapy for these widespread conditions affecting millions.

Navigating a Competitive Gene Therapy Landscape

REGENXBIO's strategy is built on the foundation of its proprietary NAV AAV platform, the same technology licensed by Novartis for its blockbuster spinal muscular atrophy treatment, ZOLGENSMA®. This validated platform provides a significant scientific underpinning for its entire pipeline.

However, in the fast-evolving gene therapy market, technology alone is not enough. The company's strategic partnerships with AbbVie and Nippon Shinyaku are crucial. These collaborations not only provide substantial non-dilutive funding and milestone payments, mitigating financial risk, but also leverage the global development and commercialization expertise of established pharmaceutical players.

Perhaps one of its most important strategic advantages is its investment in in-house manufacturing. The company's Manufacturing Innovation Center in Rockville is already producing commercial-scale batches of RGX-202. This end-to-end capability is a critical differentiator, providing control over quality, scalability, and cost, and helping to avoid the manufacturing bottlenecks that have plagued many other gene therapy companies. This readiness is essential as REGENXBIO prepares for potential commercial launches of multiple products in the coming years.

Investor Sentiment at a Crossroads

Despite the promising pipeline and strategic positioning, REGENXBIO's stock performance has been a source of frustration for investors. The company's stock (RGNX) was trading at $8.08 on February 25, significantly below its 52-week high of $16.19 and its 200-day moving average. This market performance appears disconnected from the overwhelmingly positive sentiment among Wall Street analysts.

The consensus rating for RGNX remains a "Strong Buy," with average 12-month price targets suggesting a potential upside of over 250% from its current price. Analysts point to the imminent approval of RGX-121, the blockbuster potential of RGX-202 and ABBV-RGX-314, and the company's strong manufacturing capabilities as reasons for their bullish outlook. Yet, recent price target reductions from several investment banks, even while maintaining "Buy" ratings, signal a degree of market caution.

This divergence sets the stage for the March 5 earnings call. The event will be a critical opportunity for REGENXBIO's leadership to bridge the gap between its operational achievements and its market valuation. Investors will be listening intently for clear updates on the RGX-121 approval status, firm timelines for other key data readouts, and a confident articulation of the company's commercial strategy and long-term financial plan. The company's ability to execute on its ambitious goals in the coming months will ultimately determine whether it can fulfill the promise held within its pioneering gene therapies.